GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EGEIRO Pharma (XPAR:ALVET) » Definitions » Notes Receivable

EGEIRO Pharma (XPAR:ALVET) Notes Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is EGEIRO Pharma Notes Receivable?

EGEIRO Pharma's Notes Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


EGEIRO Pharma Notes Receivable Historical Data

The historical data trend for EGEIRO Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EGEIRO Pharma Notes Receivable Chart

EGEIRO Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - - -

EGEIRO Pharma Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EGEIRO Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


EGEIRO Pharma Notes Receivable Related Terms

Thank you for viewing the detailed overview of EGEIRO Pharma's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


EGEIRO Pharma Business Description

Traded in Other Exchanges
N/A
Address
Avenue Jean Mermoz 32/1, Gosselies, BEL, 6041
EGEIRO Pharma is a biopharmaceutical company. The company is focused on the clinical development of drugs for Idiopathic Pulmonary Fibrosis, a chronic, devastating, and fatal disease characterized by the deterioration of lung function.

EGEIRO Pharma Headlines

No Headlines